研究者情報

キクチ　エイジ   KIKUCHI EIJI   菊地栄次    所属   医学部医学科 腎泌尿器外科学    職種   主任教授
言語種別	日本語
発表タイトル	JAVEMACS chart review study of avelumab maintenance for advanced urothelial carcinoma (aUC): analyses by prior platinum-based chemotherapy (PBC) characteristics
会議名	第112回日本泌尿器科学会総会
学会区分	全国規模の学会
発表形式	ポスター掲示
発表者・共同発表者	Endo Yuki, Kitamura Hiroshi, Hatakeyama Shingo, Nishihara Kiyoaki, Masumori Naoya, Fujita Kazutoshi, Miyake Hideaki, Negishi Takahito, Kobayashi Mizuki, Furukawa Junya, Shono Michihiro, Kobayashi Takashi, Kikuchi Eiji
発表年月日	2025/04/17
開催地 （都市, 国名）	福岡県福岡市
開催期間	2025/04/17～2025/04/19
概要	[Object] In Japan, avelumab maintenance treatment (tx) is approved for curatively unresectable UC not progressed after PBC. We report subgroup analyses from the JAVEMACS chart review study of avelumab maintenance tx by characteristics of first-line (1L) PBC. [Methods] In this multicenter retrospective study, medical charts of patients (pts) with aUC who started avelumab maintenance tx after 1L PBC between Feb 2021 and Dec 2023 were reviewed. [Results] Of 354 pts, no. of 1L PBC cycles was 1-3, 4, 5-6, or ≧7 in 20.1%, 58.2%, 17.2%, and 4.5%; in these subgroups, PBC was gemcitabine (G) + cisplatin (C)/G + carboplatin (Ca) in 54.9%/38.0%, 52.9%/34.5%, 62.3%/24.6%, and 75.0%/25.0%; median overall survival (OS; 95% CI) from the start of avelumab was 25.0 (15.2-not estimable [NE]), NE (29.3-NE), 31.2 (18.0-NE), and 23.6 (19.3-NE) mo; and second-line (2L) tx was received by 59.2%, 56.3%, 55.7%, and 62.5% (enfortumab vedotin [EV]/PBC in 69.0%/21.4%, 68.1%/19.0%, 58.8%/32.4%, and 60.0%/0.0%). In all pts, best response to PBC was complete response, partial response, or stable disease in 9.0%, 51.7%, and 39.3%; in these subgroups, PBC was GC/GCa in 65.6%/25.0%, 57.4%/27.9%, and 51.8%/41.7%; median OS (95% CI) from the start of avelumab was NE (30.6-NE), 31.2 (22.6-NE), and 26.5 (20.2-NE) mo; and 2L tx was received by 53.1%, 55.7%, and 59.7% (EV/PBC in 64.7%/23.5%, 62.7%/27.5%, and 71.1%/12.0%). [Conclusions] In this descriptive analysis of real-world data from pts with aUC in Japan, similar OS was observed across subgroups defined by 1L PBC cycles or best response to 1L PBC.